Belgian pharma company UCB will receive the ‘at risk co-development funding’ to directly finance six drug projects, in a deal the bank says showcases the new InnovFin scheme’s aim of boosting European innovation
Research and innovation is low on the agenda for MEPs elected to represent radical parties – if it features at all. With the EU’s new legislature facing an array of science-related policy, will this disinterest matter?